Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Conditional approval for Sunrise Technologies:

This article was originally published in Clinica

Executive Summary

The FDA has given Sunrise Technologies conditional approval to treat both of a patient's eyes on the same day using its laser vision correction system during clinical studies. The company had originally received FDA approval to treat the second eye after a six-month rest period following the first treatment. The FDA has asked Sunrise to make a minor change to the study protocol. The move follows requests from surgeons and patients wanting to have immediate treatment for the second eye after receiving initial treatment.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts